Company*
(Country,
Symbol)

Company*
(Country,
Symbol)

Type/Product Area

Terms/Details (Date)


Aastrom
Biosciences
Inc.
(ASTM)

Neoprobe Corp.
(OTC BB:NEOP)

Development collaboration for a new immune system cell therapy product for cancer treatment

Collaboration will join Neoprobe's lymph node lymphocyte cell technology with Aastrom's AastromReplicell system lymphocyte production technologies (6/5)

Abgenix Inc.
(ABGX)

Agensys Inc.*

Research collaboration option and license agreement under which the companies will develop fully human monoclonal antibody therapies against selected cancer antigen targets

Agensys has option rights to exclusive product licenses for up to 25 targets during the five-year collaboration; Abgenix will receive research license payments and could receive additional fees and milestone payments, as well as royalties; Agensys will be responsible for product development, manufacturing and commercialization (8/14)

Abgenix Inc.
(ABGX)

Biogen Inc.
(BGEN)

Agreement to generate fully human monoclonal antibodies for up to 15 Biogen-supplied antigen targets

Abgenix will receive up-front research payments, possible license and milestone payments and royalties on product sales (6/13)

Abgenix Inc.
(ABGX)

Centocor Inc.
(unit of Johnson
& Johnson)

Expanded research agreement using Abgenix's XenoMouse technology

The technology will be used to generate fully human monoclonal antibody therapies against multiple antigen targets in a variety of indications (6/8)

Affymetrix
Inc.
(AFFX)

Orchid
BioSciences
Inc.
(ORCH)

Agreements expanding their collaboration to combine Orchid's primer extension technology with the Affymetrix GeneChip GenFlex Tag Array in Orchid's SNPcode genotyping kits

Affymetrix will supply GenFlex arrays to Orchid, which will provide SNPcode-based genotyping services to its customers and distribute GenFlex arrays; Affymetrix also granted Orchid a nonexclusive license to make and sell products incorporating its universal Tag sequences (8/7)

Albany
Molecular
Research Inc.
(AMRI)

Cubist
Pharma-
ceuticals
Inc.
(CBST)

Research and licensing agreement for the discovery of a new class of anti-infective drugs designed to break through the resistance of stubborn microorganisms

AMRI is entitled to milestone fees and royalties; Cubist obtains worldwide rights to develop and market resulting drugs (8/20)

Albany
Molecular
Research Inc.
(AMRI)

Rigel
Pharma-
ceuticals Inc.
(RIGL)

Agreement for medicinal chemistry services to support and accelerate Rigel's product development

Albany will provide its expertise; financial details were not disclosed (5/31)

AlphaGene
Inc.*

Questar*

Bioinformatics outsourcing and small-molecule research collaboration

AlphaGene will offer putative proteins; Questar will provide bioinformatics support for structure determination, pathway identification, small-molecule ligand library creation and in silico screening of the small molecules; Questar also will make an equity investment in AlphaGene (6/18)

AltaRex Corp.
(Canada; OTC
BB:ALXFF;
TSE:AXO)

Epigen Inc.*

Planned collaboration to develop antibody-based treatments for up to 12 cancers associated with the human carcinoma antigen

No money will be exchanged; companies expect to enter a definitive agreement within 60 days and to begin testing within six months (6/6)

Amsterdam
Molecular
Therapeutics
BV
(the Netherlands)*

Xenon
Genetics
Inc.
(Canada)*

Exclusive sublicense and research agreement in a deal that gives AMT access to technology and intellectual property relating to lipoprotein lipase LPL

AMT and Xenon will join forces in a preclinical research program for LPL gene therapy; AMT will be responsible for further development and commercialization (8/21)

Aphios Corp.*

ITC/
Immune
Technology*

Exclusive worldwide development, manufacturing and commercialization collaboration centered on a natural therapeutic for hepatitis C

The companies will share costs and revenues associated with research, development and marketing (6/20)

Arakis Ltd.
(UK)*

SkyePharma
plc
(UK; SKYE;
LSE:SKP)

Agreement to jointly develop a novel tissue-remodeling agent for treating chronic obstructive pulmonary disease

Arakis will contribute initial intellectual property for AD 313, and SkyePharma will contribute its inhalation formulation and device technology (7/16)

Arena
Pharmaceuti-
cals Inc.
(ARNA)

ICI group
(UK)*

Agreement to apply Arena's CART technology to olfactory and gustatory G protein-coupled receptors

The initial stage of research will last at least six months; Arena will use CART to develop olfactory and/or gustatory GPCR assays and then screen compounds (7/9)

Arena
Pharmaceuti-
cals Inc.
(ARNA)

TaiGen
Biotechnology
Co.
(Taiwan)*

Licensing agreement for G protein-coupled receptor research

Arena gets about $7M up front (8/20)

Arius
Research Inc.
(Canada;
CDNX:YAR)

QualTek
Molecular
Laboratories*

Agreement to conduct target
validation studies for Arius'
cancer-killing antibodies, AR-460-23 and AR5LAC-20

Financial terms were not disclosed (7/5)

Atrix
Laboratories
Inc.
(ATRX)

Human
Genome
Sciences
Inc.
(HGSI)

Agreement to develop a sustained-released formulation of an HGS protein with Atrix's Atrigel Depot drug delivery system

HGS will provide funding and the work will be performed at Atrix's facility (8/15)

Aurora
Biosciences
Corp.
(ABSC)

Hyseq Inc.
(HYSQ)

Two-year agreement for screening Hyseq's orphan secreted protein collection

Aurora will get up-front payments, licensing fees and technology access fees; it also could receive milestones and royalties (7/11)

Avecia
Biotechnology
(UK)*

XOMA Ltd.
(XOMA)

Licensing agreement for patented bacterial cell expression system technology

Technology will help Avecia's customers identify and develop the right microbial expression technology for new protein therapeutics (6/6)

Azign
Bioscience
A/S
(subsidiary
of Neurosearch
A/S; Denmark)*

Qbiogene Inc.
(Canada)*

Licensing agreement for patent rights for use within the reagent market

Transaction includes the sale of stock, customer files and customer service systems (5/29)

BD Biosciences
(a division of
Becton, Dickinson
and Co.;
NYSE:BDX)

Dyax Corp.
(DYAX)

Agreement to discover antibodies using Dyax's phage display technology

BDB will have the exclusive right to market the Dyax antibodies as research products to the life science market; Dyax retains all rights to use the antibodies in the therapeutic field (6/13)

Biogen Inc.
(BGEN)

ICOS Corp.
(ICOS)

Collaboration to develop and commercialize oral therapeutics to treat inflammatory conditions

Companies will split profits equally and will co-promote products, as well as share in the costs of development; ICOS will receive an $8M up-front payment, as well as milestone payments (7/16)

Biomax
Informatics
AG
(Germany)*

Millennium
Pharmaceuti-
cals Inc.
(MLNM)

Licensing agreement for the BioRS Integration and Retrieval Plus system

Millennium will use the high-speed data retrieval system as a bioinformatics tool as part of its existing technology platform (7/9)

BioMimetic
Pharmaceuti-
cals Inc.*

ZymoGenetics
Inc.*
and Harvard
Medical School

Patent licensing agreements for BioMimetic's lead products

The agreement includes rights to about 30 U.S. patents (6/5)

Bionomics
Ltd.
(Australia)*

Ozgene Pty.
Ltd.
(Australia)*

Strategic alliance to develop treatments involving three genes believed to be involved in breast cancer

Bionomics owns the rights to the genes; Ozgene will contribute genetic tools and models to help with the development work, in return for a share of the royalties (6/13**)

BioReliance
Corp.
(BREL)
MDG)

MediGene
Inc.
(subsidiary
of MediGene
AG; Germany;
Neuer Markt:

Agreement in which BioReliance will produce clinical supplies of herpes simplex virus-derived G207 and NV1020

MediGene will develop both products; BioReliance will provide manufacturing and testing services for the products and production will occur in BioReliance's facility in Rockville, Md. (8/16)

Blue Heron
Biotechnology
Inc.*

Amgen Inc.
(AMGN)

Exclusive worldwide license agreement to a gene synthesis patent issued to Amgen

Blue Heron is the sole licensee and has the right to sublicense; Amgen retains rights to practice under the patent (7/10)

Boston Probes*

Human Genetic
Signatures
Pty Ltd.
(Australia)*

Development and license option agreement focused on epigenetics and personalized medicines

Boston Probes will grant Human Genetic Signatures a license to use and sell products based on Boston Probes' peptide nucleic acid technology in return for an equity stake, as well as milestone payments and royalties (6/25)

Cambridge
Antibody
Technology
Group plc
(UK; LSE:CAT)

Xerion
Pharmaceuti-
cals GmbH
(Germany)*

Licensing agreement for CAT's human phage antibody libraries and underlying intellectual property

Xerion will use the technology for target discovery and validation and for functional proteomics work; CAT received an undisclosed fee (6/5)

Celera
Genomics
Group
(NYSE:CRA)

DNA
Sciences Inc.*

Multiyear subscription agreement for Celera's database products

DNA Sciences will access the Celera Discovery System to use Celera's database products, bioinformatics systems and other discovery tools in its research (6/15)

Celera
Genomics
Group
(NYSE:CRA)

SomaLogic*
SomaLogic's
Selex process

Multiyear collaboration, giving Celera access to aptamers and aptamer arrays developed through

The collaboration also provides SomaLogic access to sequencing and proteins for developing aptamers (8/16)

Cepheid
Inc.
(CPHD)

Environmental
Technologies
Group Inc.*

Collaboration to develop biological-agent detection systems for military and other domestic preparedness applications

The systems will be manufactured and marketed on a worldwide basis by ETG and its sister company, Graseby Dynamics Ltd., under royalty-bearing licenses (8/13)

Charles River
Laboratories
International
Inc.
(NYSE:
CRL)

Sangamo
BioSciences
Inc.
(SGMO)

Technology partnership agreement to apply Sangamo's gene regulation technologies to the creation of transgenic rat research models

The collaboration initially will involve the creation of transgenic rat research models to use in developing drugs for cancer (7/12)

Chiron Corp.
(CHIR)

Genetronics
Biomedical
Corp.
(AMEX:
GEB)

Collaborative agreement to explore using Genetronics' electroporation platform to deliver certain DNA vaccines into cells in vivo

Financial details were not disclosed (7/3)

CollaGenex
Pharmaceuti-
cals Inc.
(CGPI)

Atrix
Laboratories
Inc.
(ATRX)

Exclusive licensing and marketing agreement to market Atrix's dental products, Atridox, Atrisorb-FreeFlow and Atrisorb, in the U.S.

Atrix will manufacture the products at an agreed transfer price and will receive royalties on future net sales; CollaGenex paid a $1M up-front licensing fee; Atrix purchased 330,556 newly issued shares of CollaGenex stock at a premium to the market price (8/27)

Commonwealth
Biotechnologies
Inc.
(CBTE)

bayMountain
Inc.*

Agreement to develop and commercialize methods to help interpret and mine the data present in genome databases

The companies signed a letter of intent to develop and commercialize the methods (7/23)

Consensus
Pharmaceuti-
cals Inc.*

Vertex
Pharmaceuti-
cals Inc.
(VRTX)

Collaborative agreement in which Consensus will provide substrates and chemical analysis of the catalytic site requirements for 10 targets in the protease gene family

Agreement also will entail the cloning, production and kinetic assessment of novel protease targets; Vertex has the right to develop and market resulting products; Consensus will receive certain research support and milestone payments (7/9)

Crucell NV
(the Netherlands;
CRXL)

Selective
Genetics Inc.*

Licensing and production agreement to Crucell's PER.C6 cell line

Crucell will manufacture clinical-grade batches of the PER.C6-derived gene therapy product using its human cell line production platform; Crucell will receive up-front and annual payments, as well as additional fees and royalties (6/26)

Crucell NV
(the Netherlands;
CRXL)

Vaxin Inc.*

Collaboration to develop two new types of vaccines suitable for injection-free administration

Companies will combine Crucell's PER.C6 cell line and related vaccination technology with Vaxin's skin delivery system for vaccines, EasyVax; they will share profits and costs (6/28)

Curis Inc. (CRIS)

Micromet AG*
(Germany)

Joint research, product development and technology exchange alliance combining the companies' expertise to find targets for antibody development

Curis will receive a $14M up-front payment, and also gain exclusive rights to Micromet's single-cell genomics technology for stem cell and genomics research (7/3)

CV
Therapeutics
Inc.
(CVTX)

Incyte
Genomics
Inc.
(INCY)

Expanded 1998 research agreement to focus on identifying genes involved in the development of atherosclerosis and coronary artery disease

CVT will develop biological models to study genes implicated in cardiovascular disease, and will supply mRNA from these models to Incyte, which will analyze them (8/27)

Cytochroma
Inc.
(Canada)*

Allergan Inc.
(NYSE:AGN)

Expanded research, development and license agreement to develop inhibitors of retinoic acid metabolism

The agreement extends the period of the exclusive research collaboration for up to three years and includes additional milestone payments and increased royalty streams on product sales (7/31)

DeCode
genetics Inc.
(Iceland;
DCGN)

Affymetrix
Inc.
(AFFX)

Collaboration aimed at developing DNA-based tests to predict the responsiveness of patients to treatments for common diseases, including high cholesterol, depression, asthma, hypertension, breast cancer, schizophrenia and migraines

The work will combine deCode's population-based approach to pharmacogenomics and Affymetrix's GeneChip technology; the value of the deal lies in the sales of the product, rather than up-front payments (7/24)

DeCode
genetics Inc.
(Iceland;
DCGN)

Applied
Biosystems
Group
(NYSE:ABI)

Three-year alliance to combine deCode's bioinformatics tools for genotypic analysis and Applied Biosystems' bioanalytical instruments to build capabilities for DNA research

Companies intend to adapt deCode's genotyping software suite for integration with Applied's laboratory management software to provide customizable solutions for the generation, management and analysis of genotyping data (7/19)

Discovery
Partners
International
Inc.
(DPII)

Maxia
Pharmaceuti-
cals Inc.*

Agreement focusing on a new class of biological targets

Maxia has exclusive rights to develop and commercialize all of the compounds resulting from the deal (7/19)

DNAPrint
genomics Inc.
(OTC BB:DNAP)

DNAPRO
SDN BHD
(Malaysia)*

Joint venture to expand DNAPrint's pharmacogenomics presence overseas

The joint venture is called DNAPrint genomics SDN BHD and will devote its efforts to the development of genomics-based products geared for Malaysian, Indonesian and other South Asian populations (7/17)

DNAPrint
Genomics Inc.
(OTC BB:DNAP)

Pharsight
Corp.
(PHST)

Contract that will allow DNAPrint to accelerate its pharmacogenomics research and product development

Pharsight will supply DNAPrint with clinically phenotyped specimens from patients taking a variety of variably efficacious medications (8/24)

DoubleTwist
Inc.*

GeneProt
Inc.*

Licensing agreement for Double-Twist's Prophecy suite for its proteomics research

GeneProt also licensed the commercial version of the GeneCards database (8/23)

Dragon
Pharmaceuti-
cals Inc.
(OTC
BB:DRUG)

Alphatech
Bioengineering
Ltd.
(Hong
Kong)*

Rights agreement for technology related to the production of a hepatitis B vaccine

The purchase price for the technology, which involves the application of genetic techniques for the expression and purification of recombinant hepatitis B vaccine protein using Chinese hamster ovary cells, was $4M (6/11)

Entelos Inc.*

Compaq
Computer
Corp.
(NYSE:CPQ)

Three-year agreement that will provide technology to support new drug development and disease research

Entelos will use Compaq's AlphaServer running the Tru64 UNIX and Compaq ProLiant servers running Linux as the computational platforms for its high-throughput PhysioLab systems (8/15)

Epigenomics
AG
(Germany)*

Cancer
Research
Ventures Ltd.
(UK)*

Worldwide exclusive licensing agreement for a DNA methylation-based diagnostic test

Epigenomics will develop and commercialize the novel methylation detection assay as an alternative technology for the development of diagnostic tests (7/3)

Epimmune
Inc.
(EPMN)

Biosite Inc.
(BSTE)

Nonexclusive license agreement for the Padre R technology

Biosite intends to develop these antibodies for use in its products and for use in collaborations (8/20)

Epimmune
Inc.
(EPMN)

Pharmexa
A/S
(Denmark;
CSE:PHARMX)

Non-exclusive license agreement to PADRE technology

The license covers Pharmexa's use of PADRE toward five target antigens; financial terms include up-front fees, product sales royalties and milestone payments (6/27)

Evotec OAI
(Germany; unit
of Evotec Bio-
systems AG;
Neuer Markt:
EVT)

MelTec GmbH
(Germany)*

Joint venture that will specialize in the discovery and development of treatments for autoimmune diseases and cancer

The venture will combine Evotec's discovery platform and MelTec's Whole-Cell Protein Fingerprinting proteomics technology; ownership of the new company will be split evenly (6/19)

Exact
Sciences
Corp.
(EXAS)

Laboratory
Corp. of
America
Holdings
(NYSE:LH)

Agreement for the licensing of Exact's genomics-based technologies to LabCorp

Exact will receive an up-front payment and licensing fees on the amount of testing performed (7/11)

Fludigm Corp.*

Axon
Instruments
Inc.*

Collaboration combining Fludigm's expertise in microfluidics with Axon's instrumentation knowledge

Companies will develop chips that capture and manipulate individual cells (7/2)

Galapagos
Genomics NV
(the Nether-
lands)* (VRTX)

Vertex
Pharmaceuti-
cals Inc.

Research collaboration in which Galapagos will provide custom-based recombinant adenoviruses for protein targets of interest

Vertex will use the adenoviruses to characterize protein activity within targeted biological pathways (8/22)

Gene Logic
Inc.
(GLGC)

PsychoGenics
Inc.*

Subscription agreement to a CustomSuite of the GeneExpress Suite, as well as a collaboration

Collaboration is focused on central nervous system tissue samples (7/3)

GeneMachines
Inc.*

Incyte
Genomics Inc.
(INCY)

Licensing agreement to U.S. patents and their foreign equivalents that cover fundamental methods for fabricating microarrays of biological samples on solid substrates

The agreement will enable GeneMachines to sell its OmniGrid and OmniGrid Accent microarrays with a label license for research use that allows end users to practice the methods for printing microarrays (7/23)

Genencor
International
Inc.
(GCOR)

Epimmune
Inc.
(EPMN)

Collaboration for the development of vaccines against hepatitis C, hepatitis B and human papillomavirus

Collaboration is for 30 months and is potentially worth $60M (7/10)

Genencor
International
Inc.
(GCOR)

Gyros AB
(Sweden)*

One-year collaboration to apply Gyros' microfluidic technology to Genencor's screening capabilities

Gyros will design applications and compact discs for Genencor's screening assays; Genencor will serve as a technical evaluation site (5/25)

Genencor
International
Inc.
(GCOR)

Phogen Inc.
(joint venture
company of
Xenova Group
plc; UK; XNVA;
LSE:XEN)

Licensing agreement for the VP22 technology

Genencor will use the technology in its vaccines programs; Phogen will receive upfront license fees, research and development funding and annual license maintenance fees, as well as milestone payments; the deal is potentially worth more than $21M (8/14)

Genmab A/S
(Denmark;
CSE:GEN)

DeCode
genetics Inc.
(Iceland; DCGN)

Collaboration covering cardiovascular and inflammatory diseases, as well as cancer, and a separate agreement to develop a DNA-based test to predict individual clinical response to HuMax-CD4

DeCode will contribute novel targets and the companies will share development costs and profits; in the second agreement, Genmab will provide research funding and potential milestone payments (6/12)

Genomics
Collaborative
Inc.*

ActivX
Bioscience
Inc.*

Partnership to identify and validate proteins and gene targets associated with colon cancer

The goal is to develop a joint research program using activity-based proteomics on colon cancer specimens to identify new targets suited for diagnostic and therapeutic development (8/8)

Genomics
Collaborative
Inc.*

Exelixis Corp.
(EXEL), Pharma-
cia Corp.
(NYSE:
PHA) and Glaxo-
SmithKline plc
(UK), along with two others

Agreements for GCI Access designed to provide researchers with access to a database of clinical data and DNA, tissue and sera samples

GCI Access enables researchers to accelerate the validation process (8/22)

Genomic
Solutions
Inc.
(GNSL)

NuTec
Sciences Inc.*

Collaborative agreement to expand and enhance the bioinformatics technology capabilities of Genomic Solution's GeneTAC Biochip system

NuTec will work with Genomic Solutions to design and develop the new software (7/19)

Genomic
Solutions
Inc.
(GNSL)

Proteo-
Metrics
Inc.*

Agreement to develop proteomics software

The companies will create a bioinformatic product integrating Genomic Solutions' Investigator Protein Warehouse data integration software with ProteoMetrics' Radars system for mass spectrometry data analysis (7/30)

Genomics
One
Corp.
(Canada;
MSE:GNX)

WITA
Proteomics
AG
(Germany)*

Strategic marketing agreement for WITA's high-resolution proteomics platform

Genomics One will market the platform in North America (6/8)

Genta Inc.
(GNTA)

EpiGenesis
Pharmaceuti-
cals Inc.*

Licensing agreement for several patents involving methods, compositions and processes for in vitro and in vivo inhibition of protein synthesis by antisense oligonucleotides

The nonexclusive agreement includes an up-front cash payment to Genta, along with royalty payments (7/25)

Genzyme
Diagnostics
(unit of Genzyme
General; GENZ)

SYN-X
Pharma
Inc.
(Canada;
CDNX:SYY)

Agreement to develop, manufacture and commercialize a technology for diagnosing, distinguishing, managing and monitoring stroke

The agreement supercedes prior agreements between the businesses regarding the technology and resolves all disputes between them (7/10)

Genzyme
Molecular
Oncology
(GZMO)

BruCells
SA/NV
(Belgium)*

Licensing agreement for patent rights to cover the fusion of dendritic cells and tumor cells

Genzyme will sponsor a two-year research program at BruCells related to the licensed technology (6/4)

Graffinity
Pharma-
ceutical
Design
GmbH
(Germany)*

Biosearch
Italia SpA
(Italy)*

Alliance to discover and develop antibiotic products

Biosearch will use Graffinity's drug discovery technology to identify compounds against targets identified by Biosearch (8/6)

Gyros AB
(Sweden)*

Affibody AB
(Sweden)*

Strategic alliance to develop and commercialize an integrated and automated microfluidics-based protein microarray platform

Platform will combine its CD-based microlaboratories with Affibody's high-throughput, high-sensitivity protein microarrays (5/31)

HiberGen
Ltd.
(Ireland)*

Sequenom
Inc.
(SQNM)

Exclusive license agreement to SNaPIT genotyping technology for use with mass spectrometry

Sequenom has the right to develop and commercialize reagent kits and software based on HiberGen's technology for use with its MassARRAY high-throughput screening technology (7/9)

Hybridon
Inc.
(OTC
BB:HYBN)

Isis
Pharma-
ceuticals
Inc.
(ISIP)

Agreement for each other's intellectual property

Isis is paying $34.5M ¿ $15M up front and $19.5M in Isis stock over two years ¿ for an exclusive license to all of Hybridon's antisense chemistry and delivery patents and technology; Hybridon gains access to Isis RNase H patents (5/25)

Hybrigenics
SA
(France)*

Oxford
Glyco-
Sciences
plc
(UK;
OGSI;
LSE:OGS)

Collaboration to improve the selection and prioritization of Oxford's candidate targets, with the potential to discover new targets

Hybrigenics will use its high-throughput functional proteomics technology to identify proteins that interact with a selection of Oxford targets; the data will be owned equally by both companies; Oxford will provide research funding and will have an option to obtain the exclusive rights to commercialize resulting data (7/23)

ICOS Corp.
(ICOS)

Array
BioPharma
Inc.
(ARRY)

Agreement to discover and develop small-molecule drugs directed at disease targets containing the I-domain allosteric site structural motif

ICOS will provide research funding for two years; it also will be responsible for clinical development and commercialization; Array will receive milestones and royalties (8/14)

ICOS Corp.
(ICOS)

Seattle
Genetics
Inc.
(SGEN)

Agreement in which Seattle Genetics will perform process development scale-up and GMP manufacturing on SGN-15; also, an agreement to develop SGN-30

Financial terms were not disclosed (8/14)

Incyte
Genomics
Inc.
(INCY)

Corvas
International
Inc.
(CVAS)

Multiyear subscription agreement for the LifeSeq Gold database

The database will be used to advance Corvas' cancer research and development programs focused on proteases (8/1)

Incyte
Genomics
Inc.
(INCY)

Iconix
Pharma-
ceuticals
Inc.*

Collaboration to develop and commercialize a next-generation chemogenomic information product

Incyte will market ChemExpress and will make an equity investment in Iconix; Iconix will integrate Incyte's LifeExpress lead database into ChemExpress (5/30)

Incyte
Genomics
Inc.
(INCY)

Secant
Technologies
Inc.*

Partnership to market and further develop Incyte's Genomics Knowledge Platform

Secant gains the exclusive license to assume further development and marketing of GKP; Incyte will make an equity investment in Secant (7/9)

Inpharmatica
Ltd.
(UK)*

Serono SA
(Switzerland;
NYSE:SRA)

Two-year collaborative agreement for the discovery of novel protein therapeutics

Serono will provide research funding and will have the right to select an unlimited number of proteins for clinical development and commercialization, as well as develop antibodies and small molecules against identified protein targets; Inpharmatica will receive a series of undisclosed payments, and potential royalties; total milestone payments could exceed $20M (7/12)

Inspire
Pharmaceu-
ticals Inc.
(ISPH)

Allergan Inc.
(NYSE:AGN)

Licensing, development and marketing deal for dry-eye products

The agreement covers Inspire's INS365 Ophthalmic and Allergan's Restasis; Inspire could receive up to $39M in up-front and milestone payments (6/27)

Inspire
Pharmaceu-
ticals Inc.
(ISPH)

Genentech
Inc.
(NYSE:
DNA)

Agreement returning rights to P2Y2 agonists to treat respiratory disorders

The return of rights will cost nothing for Inspire, which already received $16M from the deal started in December 1999 (6/20)

InterMune
Inc.
(ITMN)

Amgen Inc.
(AMGN)

Licensing agreement to the approved hepatitis C therapeutic Infergen

InterMune licensed Infergen for $21M in upfront payments, $8M in near-term milestones and royalties on sales; InterMune gained rights to develop and commercialize Infergen and an early stage pegylated interferon product candidate under development by Amgen (6/15)

Invitrogen
Corp.
(IVGN)

Cell Genesys
Inc.
(CEGE)

Licensing agreement for its lentiviral gene delivery technology for commercialization in the research market

Cell Genesys will receive royalties on sales and a share of any sublicense payments (8/13)

Isis
Pharmaceu-
ticals Inc.'s
GeneTrove
division (ISIP)

Celera
Genomics
Group
(NYSE:
CRA)

Agreement to identify the roles of more than 200 novel genes for Celera

Celera will select which genes are studied and GeneTrove will perform the work using its High-Throughput Gene Functionalization system; the genes will be evaluated for their roles in cancer, angiogenesis, inflammation and metabolic diseases (7/16)

KS Biomedix
Holdings plc
(UK)*

Babraham
Bioscience
Technologies
Ltd.
(UK)*

Agreement to form a company called Discerna Ltd. to be located in Cambridge, UK

Discerna will be an equal joint venture bringing together Babraham's ribosome display technology and KSB's therapeutic targets; KSB will provide funding for two years and certain therapeutic targets; Babraham will provide Discerna with exclusive worldwide rights to develop its ribosome display technology (6/12)

Large Scale
Biology Corp.
(LSBC)

Plant
Bioscience
Ltd.
(UK)*

Agreement to combine Large Scale's high-throughput gene discovery capabilities with Plant Bioscience's portfolio of technologies in the field

Large Scale gains an exclusive license to certain viral-delivered gene-silencing and overexpression technologies and an exclusive license to certain other viral-delivered technologies (6/21)

Lexicon
Genetics
Inc.
(LEXG)

Immunex
Corp.
(IMNX)

Two-year drug target validation agreement in which Lexicon will use its gene targeting technologies to develop knockout mammalian models for targets in Immunex's internal drug discovery programs

Lexicon will receive an up-front technology access fee and annual research funding, as well as milestones and royalty payments (7/31)

Lexicon
Genetics
Inc.
(LEXG)

Incyte
Genomics
Inc.
(INCY)

Collaboration aimed at building each other's technologies and developing therapeutic protein drug products

Each company will be entitled to milestone and royalty payments; each company will select 250 secreted proteins for functional characterization and Lexicon will apply its in vivo mammalian validation technologies to determine the therapeutic utility of the proteins (6/28)

LION
bioscience
AG
(Germany;
LEON)

MDL
Information
Systems Inc.*

Software licensing and reselling agreement

LION will license a range of MDL's informatics applications and databases in order to develop and commercialize software applications to interface with MDL's products; MDL will be the exclusive reseller for LION's iDEA product line (7/19)

Luminex
Corp.
(LMNX)
(subsidiary of
Techne Corp.)*

Research and
Diagnostic
Systems Inc.

Multiyear partnership to develop and market reagents based on Luminex's LabMAP technology

Research and Diagnostic Systems gets a worldwide nonexclusive license in return for an up-front payment and royalties (6/6)

Lynx
Therapeutics
Inc.
(LYNX)

BASF-LYNX
Bioscience AG
(joint venture
between Lynx
and BASF AG;
Germany)*

Extended technology license agreement through Dec. 31, 2007

The license extends BASF-LYNX's right to use Lynx's Massively Parallel Signature Sequencing and Megasort technologies nonexclusively; BASF-LYNX will pay Lynx a multimillion-dollar technology license fee (7/18)

Martek
Biosciences
Corp.*

Syngenta
(Switzerland)*

Joint research and development project to find and characterize genes from microalgae

Companies have cross-royalty arrangements and Martek has exclusive worldwide commercialization rights to use the genes in microbial production of docosahexaenoic acid; Syngenta's Torrey Mesa Research Institute has rights to use the genes in agricultural crop species (5/29)

MDS Inc.
(Canada;
NYSE:MOZ;
TSE:MOS)

Signature
BioScience
Inc.*

Agreement that calls for MDS to develop Signature's microwave spectroscopy instrumentation

Up-front fees to Signature will total $10M, and other milestone and royalty payments also are part of the package; MDS gains exclusive license rights to commercialize research instrumentation and peripherals based on microwave spectroscopy instrumentation (8/15)

MDS
Proteomics
Inc.
(NYSE:
MDZ)

Abgenix
Inc.
(ABGX)

Collaboration to develop and commercialize antibodies for a range of diseases

Companies will receive reciprocal milestone and royalty payments; Abgenix will purchase $15M in MDS stock (6/29)

Medarex
Inc.
(MEDX)

Epicyte
Pharma-
ceutical Inc.*

Collaboration to discover, develop and commercialize antibody-based products

Medarex will use its UltiMAb Human Antibody Development System to generate antibodies to antigen targets; the companies will share the costs and the commercialization rights of any antibody therapeutics (6/25)

Medarex Inc.
(MEDX)

Genesto A/S
(Denmark)*

Agreement to discover therapeutic antibodies

Medarex will use its UltiMab System to create antibody leads to target proteins supplied by Genesto; Genesto would be responsible for commercializing any resulting products (8/15)

Medarex Inc.
(MEDX)

Genmab A/S
(Denmark;
CSE:GEN)

Expanded relationship in which Medarex will develop a fully human therapeutic antibody against inflammation with Genmab

The companies will share equally in costs of development and profits; Medarex will retain all rights and cost responsibilities for product development and commercialization in Asia (6/19)

Medarex Inc.
(MEDX)

Human
Genome
Sciences Inc.
(HGSI)

Agreement to create antibody leads usings its UltiMAb System

Medarex will get license fees, milestone payments and is entitled to royalties (7/25)

Medarex Inc.
(MEDX)

Sangamo
Biosciences
Inc.
(SGMO)

Development and commercialization agreement for fully human antibodies using cell lines that overexpress selected G protein-coupled receptors

The companies will share costs and profits from the joint effort (6/11)

MediChem
Life Sciences
(MCLS)

Elitra Phar-
maceuticals
Inc.*

Three-year joint research program to discover and develop drug candidates against microbial infections

The companies will commit resources and share rights to the program; Elitra will reimburse MediChem for research conducted and may purchase rights to drug candidates in exchange for milestone payments and royalties (6/7)

MediChem
Life Sciences
(MCLS)

Neurocrine
Biosciences
Inc.
(NBIX)

Two-year collaborative agreement in proteomics for new drug development

MediChem will crystallize and determine high-resolution 3-dimensional structures of specific G protein-coupled receptors; Neurocrine will provide access and milestone fees, as well as research funding (6/27)

Microcide
Pharmaceuti-
cals Inc.
(MCDE)

Cetek Corp.*

Collaborative research and development agreement for new classes of anti-infective agents

Microcide will pay Cetek milestones and will have worldwide development and commercialization rights on products that result from the collaboration (6/12)

Millennium
Pharmaceuti-
cals Inc.
(MLNM)

Pharsight
Corp.
(PHST)

Agreement to evaluate and apply Pharsight's computer-assisted trial design and methodologies to Millennium's drug development programs

The agreement will focus on testing and validating the utility of Pharsight's modeling and simulation software in LDP-341, a cancer treatment in Phase II trials (7/17)

MorphoSys
AG
(Germany;
Neuer Markt:
MOR)

ImmunoGen
Inc.
(IMGN)

Collaboration that grants ImmunoGen a license to MorphoSys' HuCAL technology to generate research antibodies

Agreement is an extension to an October 2000 deal; ImmunoGen will pay technology access and annual subscription fees over a four-year term (6/21)

NeoGenesis
Inc.*

Biogen Inc.
(BGEN)

Expanded agreement from target identification to the screening of drug leads from Biogen's proteins

NeoGenesis will receive up-front payments and research and development funding, as well as milestone payments and royalties (7/9)

NeoGenesis
Inc.*

Celltech
Group plc
(UK; NYSE:
CLL)

Research collaboration in which Celltech will provide the disease targets in its core therapeutic areas and NeoGenesis will use its chemical genomics technology to screen for drug leads

NeoGenesis gets a $10M equity investment from Celltech, several years of research funding, and potential milestone and royalty payments (7/12)

Neuralstem
Inc.*

MetriGenix
Inc.*

Agreement to jointly develop and market a series of neurochips as low-density, theme-based oligonucleotide microarrays based on MetriGenix's Flow-thru Chip technology

Financial terms were not disclosed (8/7)

NicOx SA
(France;
Nouveau Marche:
NICOX)

Biolipox
(Sweden)*

Research and codevelopment agreement on a class of nitric oxide-releasing respiratory therapeutics

NicOx will synthesize a series of new compounds (6/25)

Oxford
Glyco-
Sciences
plc
(UK; OGSI;
LSE:OGS)

Marconi plc
(UK; MONI;
LSE:MONI)

Joint venture to specialize in the supply, hosting and management of proteomics databases

The venture, Confirmant Ltd., will have initial funding of US$42M, which the founders will contribute equally in cash; Confirmant will pay Oxford for exclusive rights to proteome databases and a license to data analysis software (6/15)

Oxford
Glyco-
Sciences
plc
(UK; OGSI;
LSE:OGS)

NeoGenesis
Inc.*

Alliance to accelerate OGS small-molecule discovery and development against protein targets derived from its high-throughput proteomics platform

OGS will provide potential protein targets and NeoGenesis will apply its high-throughput integrated technologies for chemistry, screening and computational biology to search for leads; OGS will provide research funding, milestone payments and royalties, as well as make an equity investment in NeoGenesis (6/20)

Oxxon
Pharma-
ceuticals
Inc.*

Isis
Innovation
(technology
transfer
company at
the University
of Oxford)*

Licensing agreement for intellectual property on adenovirus vaccine technology

The license covers the worldwide exclusive use of adenovirus vaccine to boost an immune response to an antigen for therapeutic and prophylactic applications in the fields of infectious disease and cancer (7/19)

Peregrine
Pharma-
ceuticals Inc.
(PPHM)

Oakwood
Laboratories
LLC*

Joint development agreement to evaluate therapeutic agents that combine Peregrine's tumor necrosis therapy tumor-targeting technology with Oakwood's anti-cancer liposome technology

Peregrine will provide TNT antibodies and Oakwood will provide liposomes and pre-clinical testing services (7/30)

QLT Inc.
(Canada;
QLTI)

Kinetek
Pharmaceu-
ticals Inc.
(Canada)*

Research, development and license agreement for signal transduction inhibitors to treat eye, immune system and kidney diseases

QLT will make an initial C$11M equity investment in Kinetek; the deal is potentially worth C$120M (US$80M) (6/8)

QLT Inc.
(Canada;
QLTI)

Xenova
Group
plc
(UK; XNVA;
LSE:XEN)

Licensing agreement for XR9576

QLT will use the product in its oncology programs; QLT is paying a $10M license fee up front and may pay as much as $50M in milestones; it also will fund up to $45M for Phase III trials in North America and Europe; Xenova will benefit from royalties between 15% and 22% (8/14)

Quark
Biotech
Inc.*

ES Cell
International
Pte Ltd.
(Singapore)*

Joint human embryonic stem cell research program

Program will aim to discover the underlying cause of human embryonic stem cell differentiation and self-renewal (6/26)

Rosetta
Inpharmatics
Inc.
(RSTA)

Europro-
teome AG
(Germany)*

Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System

Financial terms were not disclosed (8/23)

Sangamo
BioSciences
Inc.
(SGMO)

Zycos Inc.*

Collaboration to assess the utility of Zycos' gene transfer technology for the delivery of Sangamo's zinc finger DNA-binding protein transcription factor genes in vivo

Sangamo will evaluate the effectiveness of Zycos' gene expression system and biopolymer delivery system technologies (6/27)

Seattle
Genetics
Inc.
(SGEN)

Eos
Biotechnol-
ogy
Inc.*

Agreement linking Eos' monoclonal antibodies with Seattle's toxic payload technology to provide stronger anticancer therapies

Eos will pay an up-front access fee, milestone payments and royalties on sales of resulting products (6/5)

Sequenom
Inc.
(SQNM)

Morpho-
chem
AG
(Germany)*

Agreement for two to three years that will focus on discovery and development of next-generation therapeutics to treat Type II diabetes mellitus and cancer

Each company will cover its own research costs and the two will equally share any results of the collaboration (6/7)

Sequitur
Inc.*

Rigel
Pharma-
ceutical Inc.
(RIGL)

Agreement to provide access to Sequitur's antisense functional genomics technology

The multiyear agreement stipulates a supply of Sequitur's antisense compounds, sequence selection and transfection methods will go to Rigel, which will pay research support, antisense material charges and licensing fees (8/22)

Silicon
Genetics
Inc.*

Exelixis
Inc.
(EXEL)

Licensing agreement for the GeNet database for use in Exelixis' integrated discovery platform

Licensing terms were not disclosed (8/7)

Specialty
Laborator-
ies Inc.
(NYSE:SP)

Axis-Shield
plc
(Scotland)*

Agreement for exclusive U.S. rights to a new gene-based test for predisposition to osteoporosis

The test uses a UK-based Gemini Genomics plc patent on Type 1 collagen gene (6/21)

Synt:em
(France)*

SangStat
Inc.

(SANG)

Three-year research collaboration for the discovery of next-generation RDP58 molecules

The focus of the collaboration will be to develop novel RDP58-like compounds for the inhibition of inflammation in new in vivo applications (7/12)

Syrrx Inc.*

Cubist
Pharma-
ceuticals
Inc.
(CBST)

Anti-infective drug discovery collaboration

The work will focus on bacteria and fungi (6/27)

The Genetic
Company
Inc.
(Switzer-
land)*

Discovery
Technol-
ogies
Ltd.
(Switzerland)*

Collaboration to identify precursors for drug leads to treat colon cancer

The aim is to test thousands of chemical substances in a high-throughput screen for their ability to block the activity of cellular proteins that trigger cell division (8/24)

Thermo
Finnigan
Inc.
(division
of Thermo
Electron
Corp.)*

Proteome
Systems
Inc.
(Australia)*

Partnership to develop total solutions for proteomics research

Proteome Systems will augment its integrated proteomics technology system, ProteomIQ, by incorporating several Thermo Finnigan products; Thermo Finnigan will have access to Proteome Systems' sample preparation technology for the electrospray mass spectrometer (8/22)

Trimeris
Inc.
(TRMS)

Array
BioPharma
Inc.
(ARRY)

Agreement to discover small- molecule fusion inhibitors of HIV and respiratory syncytial virus

Trimeris will screen a library of small-molecule compounds provided by Array against HIV and RSV fusion protein targets; Array will optimize lead compounds; Array will be entitled to receive payments and royalties based on achievement of certain developmental milestones (8/6)

Valentis
Inc.
(VTLS)

Lexicon
Genetics
Inc.
(LEXG)

Nonexclusive license agreement for the GeneSwitch gene regulation technology

The license is for research purposes only and involves an up-front payment and annual maintenance fees (8/1)

Vernalis
Group
plc
(UK;
LSE:VER)
Inc.*

Alcon
Labora-
tories

Agreement to explore approaches to the treatment of glaucoma

Companies will assess molecules from the Vernalis research portfolio (6/27)

Viron
Thera-
peutics
Inc.
(Canada)*

Xenova
Group
plc
(UK;
XNVA;
LSE:XEN)

Agreement to license an undisclosed anti-inflammatory protein

Terms were confidential; Xenova will move forward in research and development of the protein (6/12)

Xanthon
Inc.*

Chiron
Corp.
(CHIR)

Collaboration to explore the development of a system to detect the presence of infectious agents in clinical samples using Xanthon's technology and Chiron's nucleic acid sequences

Xanthon will conduct these studies using its electrochemical DNA detection system and Chiron's HCV insert (8/20)

Xanthon
Inc.*

Xeno-
metrix Inc.
(subsidiary
of Discovery
Partners
International
Inc.; DPII)

Worldwide license agreement for access to gene expression profiling claims in U.S. and European patents

The nonexclusive license covers the collection of gene expression profiles using all platforms, including biochips, high-density microarrays and other high-throughput methods (7/9)

Xenerex
Biosciences
(subsidiary
of Avanir
Pharmaceu-
ticals Inc.;
AMEX:AVN)

Peregrine
Pharma-
ceuticals
Inc.
(PPHM)

Agreement to generate fully human monoclonal antibodies based on three Peregrine antigen targets

Once generated, Peregrine will take responsibility for product development, manufacturing and commercialization; Xenerex will receive up-front research fees and could earn milestones and royalties on sales (6/12)

Zonagen
Inc.
(ZONA)

Bridge
Organics*

Agreement to develop a commercially viable process for a new class of compounds to treat endometriosis

The compounds, known as selective progesterone receptor modulators, were developed by the National Institutes of Health (6/15)

Zygogen
LLC*

NuTec
Sciences
Inc.*

Strategic partnership involving zebrafish

Alliance aims to accelerate Zygogen's ability to convert zebrafish into a target validation and screening model (6/15)

Zyomyx
Inc.*

BD Bio-
sciences
(division of
Becton, Dickin-
son & Co.;
NYSE:BDX)

Supply and collaboration agreement to develop high-density protein biochips

BD Biosciences will develop, manufacture and supply antibodies for Zyomyx's research platform (7/30)


Notes:

# This chart does not include agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; MSE = Montreal Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange

No Comments